Merck Signs Licensing Deal With Santen, Marking Second Deal For Japan’s Top Ophthalmology Maker
This article was originally published in PharmAsia News
Executive Summary
Japan's Osaka-based Santen Pharmaceutical April 15 signed a worldwide licensing agreement with Merck for Tapros/Taflotan (tafluprost), a treatment for glaucoma and ocular hypertension
You may also be interested in...
Merck’s New Glaucoma Drug Zioptan Faces Formidable Market Challenge
U.S. approval of the prostaglandin analogue adds to Merck’s ophthalmology portfolio, but it remains to be seen whether being preservative free confers tafluprost an advantage in a field that includes generics of the blockbuster Pfizer drug Xalatan.
Japan Earnings Roundup: Eisai Update On FDA Refusal Letter; Specialty Pharma Santen Packs A Punch In China
The PharmAsia News Japanese earnings roundup is a periodic feature highlighting major developments from Japanese pharma quarterly calls and reports. The prior installment discussed recent developments at Shionogi & Co. Ltd. and Astellas Pharma Inc. ('Japanese Earnings Roundup: Shionogi Rebounds From U.S. Acquisition Woes With C&O Pharmaceutical For China; Astellas Ponders Mirabegron's Reproductive Warning,' PharmAsia News, Aug. 2, 2011).
Japan Earnings Roundup: Eisai Update On FDA Refusal Letter; Specialty Pharma Santen Packs A Punch In China
The PharmAsia News Japanese earnings roundup is a periodic feature highlighting major developments from Japanese pharma quarterly calls and reports. The prior installment discussed recent developments at Shionogi & Co. Ltd. and Astellas Pharma Inc. ('Japanese Earnings Roundup: Shionogi Rebounds From U.S. Acquisition Woes With C&O Pharmaceutical For China; Astellas Ponders Mirabegron's Reproductive Warning,' PharmAsia News, Aug. 2, 2011).